Antisense Therapeutics Limited
Percheron Therapeutics Limited engages in the research and development of novel antisense pharmaceuticals in Australia. The company's product pipeline comprises ATL1102, an antisense inhibitor of CD49d, which is in Phase IIa clinical trial for the treatment of Duchenne Muscular Dystrophy, Limb Girdle Muscular Dystrophy R2, multiple sclerosis, asthma, and other inflammatory indications. Its produc… Read more
Antisense Therapeutics Limited (ATHJF) - Total Liabilities
Latest total liabilities as of June 2024: $5.17 Million USD
Based on the latest financial reports, Antisense Therapeutics Limited (ATHJF) has total liabilities worth $5.17 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Antisense Therapeutics Limited - Total Liabilities Trend (2001–2024)
This chart illustrates how Antisense Therapeutics Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Antisense Therapeutics Limited Competitors by Total Liabilities
The table below lists competitors of Antisense Therapeutics Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NexturnBioscience Co. Ltd
KQ:089140
|
Korea | ₩128.65 Billion |
|
Shinyoung Waco
KO:005800
|
Korea | ₩39.27 Billion |
|
RTRZY
OTCGREY:RTRZY
|
USA | $803.40 Million |
|
Bluerock Homes Trust Inc.
NYSE MKT:BHM
|
USA | $452.66 Million |
|
Home Loan Financial Corp
PINK:HLFN
|
USA | $330.26 Million |
|
GameSquare Holdings Inc.
NASDAQ:GAME
|
USA | $42.38 Million |
|
Iqstel Inc
OTCQX:IQST
|
USA | $67.11 Million |
|
Garo AB
ST:GARO
|
Sweden | Skr475.60 Million |
Liability Composition Analysis (2001–2024)
This chart breaks down Antisense Therapeutics Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.55 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.36 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Antisense Therapeutics Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Antisense Therapeutics Limited (2001–2024)
The table below shows the annual total liabilities of Antisense Therapeutics Limited from 2001 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-06-30 | $5.17 Million | +80.21% |
| 2023-06-30 | $2.87 Million | +121.38% |
| 2022-06-30 | $1.30 Million | +1.74% |
| 2021-06-30 | $1.27 Million | +55.02% |
| 2020-06-30 | $821.23K | -7.61% |
| 2019-06-30 | $888.84K | +53.02% |
| 2018-06-30 | $580.86K | -15.28% |
| 2017-06-30 | $685.65K | -8.60% |
| 2016-06-30 | $750.20K | +29.03% |
| 2015-06-30 | $581.44K | +2.16% |
| 2014-06-30 | $569.13K | +2.71% |
| 2013-06-30 | $554.10K | +30.90% |
| 2012-06-30 | $423.29K | +1.33% |
| 2011-06-30 | $417.74K | -11.39% |
| 2010-06-30 | $471.43K | -55.60% |
| 2009-06-30 | $1.06 Million | -69.93% |
| 2008-06-30 | $3.53 Million | +73.73% |
| 2007-06-30 | $2.03 Million | +529.17% |
| 2006-06-30 | $323.03K | -9.70% |
| 2005-06-30 | $357.72K | -64.87% |
| 2004-06-30 | $1.02 Million | +179.40% |
| 2003-06-30 | $364.40K | -80.33% |
| 2002-06-30 | $1.85 Million | +3301.59% |
| 2001-06-30 | $54.46K | -- |